1. In Vivo
  2. >>Global Vision

Revisiting Cell Screening To Find New Cancer Drug Combos

 
• By Mark Ratner

Evidence is slowly building of the potential of high-throughput screening of individual patient tumors to test their sensitivity and response to hundreds of combinations of cancer drugs, first in leukemia and hopefully for treating other cancers.

A handful of academic groups in Europe and the US are using high-throughput (HT) ex vivo screening to test the sensitivity of individual patient tumors to hundreds of combinations of cancer drugs – a strategy that in earlier iterations failed to predict response to therapy. HT screening is used routinely in drug discovery. Thanks to advances in nanoliter-scale sample handling and computational biology, evidence is slowly building of the potential of HT approaches to identify novel combination therapies, first in leukemia and hopefully for treating other cancers.

In the 1980s, researchers began using ex vivo cell screening to try to predict the efficacy of conventional chemotherapy. It...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

China’s Policies Prompt Reflection Among Global Medtechs As Local Players Adapt

 
• By Ashley Yeo

Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

More from In Vivo

Podcast: The Potential Of AI In Developmental Cell Biology

 
• By David Wild

In this episode, In Vivo speaks with Micha Breakstone, co-founder and CEO of Somite.AI, and Samantha Dale Strasser, VP of strategy, to explore how their techbio is applying foundation models to human cell differentiation.

A Year Of Firsts As Biosimilars Build Momentum In US

 
• By Dave Wallace

In a busy year for US biosimilars, 2025 saw more than a dozen approvals as multiple biologics faced competition for the first time – including Stelara. However, concerns persist over the lack of rivals in development for numerous brands coming off-patent, with a hope that regulatory streamlining can

Pharmatech Funding: What Corporate VCs Actually Want

 
• By David Wild

Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.